Neurological disorders and therapeutics targeted to surmount the blood–brain barrier
Jagat R Kanwar, Bhasker Sriramoju, Rupinder K KanwarNanomedicine Laboratory of Immunology and Molecular Biomedical Research, Centre for Biotechnology and Interdisciplinary Biosciences, Institute for Frontier Materials (IFM), Deakin University, Waurn Ponds, Victoria, AustraliaAbstract: We are now in...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5ffe1ee26bfe40eca32c8a61e53bef35 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:5ffe1ee26bfe40eca32c8a61e53bef35 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:5ffe1ee26bfe40eca32c8a61e53bef352021-12-02T02:31:37ZNeurological disorders and therapeutics targeted to surmount the blood–brain barrier1176-91141178-2013https://doaj.org/article/5ffe1ee26bfe40eca32c8a61e53bef352012-07-01T00:00:00Zhttp://www.dovepress.com/neurological-disorders-and-therapeutics-targeted-to-surmount-the-blood-a10344https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Jagat R Kanwar, Bhasker Sriramoju, Rupinder K KanwarNanomedicine Laboratory of Immunology and Molecular Biomedical Research, Centre for Biotechnology and Interdisciplinary Biosciences, Institute for Frontier Materials (IFM), Deakin University, Waurn Ponds, Victoria, AustraliaAbstract: We are now in an aging population, so neurological disorders, particularly the neurodegenerative diseases, are becoming more prevalent in society. As per the epidemiological studies, Europe alone suffers 35% of the burden, indicating an alarming rate of disease progression. Further, treatment for these disorders is a challenging area due to the presence of the tightly regulated blood–brain barrier and its unique ability to protect the brain from xenobiotics. Conventional therapeutics, although effective, remain critically below levels of optimum therapeutic efficacy. Hence, methods to overcome the blood–brain barrier are currently a focus of research. Nanotechnological applications are gaining paramount importance in addressing this question, and yielding some promising results. This review addresses the pathophysiology of the more common neurological disorders and novel drug candidates, along with targeted nanoparticle applications for brain delivery.Keywords: blood–brain barrier, neurological diseases, brain delivery, targeted nanoparticlesKanwar JRSriramoju BKanwar RKDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2012, Iss default, Pp 3259-3278 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Kanwar JR Sriramoju B Kanwar RK Neurological disorders and therapeutics targeted to surmount the blood–brain barrier |
| description |
Jagat R Kanwar, Bhasker Sriramoju, Rupinder K KanwarNanomedicine Laboratory of Immunology and Molecular Biomedical Research, Centre for Biotechnology and Interdisciplinary Biosciences, Institute for Frontier Materials (IFM), Deakin University, Waurn Ponds, Victoria, AustraliaAbstract: We are now in an aging population, so neurological disorders, particularly the neurodegenerative diseases, are becoming more prevalent in society. As per the epidemiological studies, Europe alone suffers 35% of the burden, indicating an alarming rate of disease progression. Further, treatment for these disorders is a challenging area due to the presence of the tightly regulated blood–brain barrier and its unique ability to protect the brain from xenobiotics. Conventional therapeutics, although effective, remain critically below levels of optimum therapeutic efficacy. Hence, methods to overcome the blood–brain barrier are currently a focus of research. Nanotechnological applications are gaining paramount importance in addressing this question, and yielding some promising results. This review addresses the pathophysiology of the more common neurological disorders and novel drug candidates, along with targeted nanoparticle applications for brain delivery.Keywords: blood–brain barrier, neurological diseases, brain delivery, targeted nanoparticles |
| format |
article |
| author |
Kanwar JR Sriramoju B Kanwar RK |
| author_facet |
Kanwar JR Sriramoju B Kanwar RK |
| author_sort |
Kanwar JR |
| title |
Neurological disorders and therapeutics targeted to surmount the blood–brain barrier |
| title_short |
Neurological disorders and therapeutics targeted to surmount the blood–brain barrier |
| title_full |
Neurological disorders and therapeutics targeted to surmount the blood–brain barrier |
| title_fullStr |
Neurological disorders and therapeutics targeted to surmount the blood–brain barrier |
| title_full_unstemmed |
Neurological disorders and therapeutics targeted to surmount the blood–brain barrier |
| title_sort |
neurological disorders and therapeutics targeted to surmount the blood–brain barrier |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/5ffe1ee26bfe40eca32c8a61e53bef35 |
| work_keys_str_mv |
AT kanwarjr neurologicaldisordersandtherapeuticstargetedtosurmountthebloodampndashbrainbarrier AT sriramojub neurologicaldisordersandtherapeuticstargetedtosurmountthebloodampndashbrainbarrier AT kanwarrk neurologicaldisordersandtherapeuticstargetedtosurmountthebloodampndashbrainbarrier |
| _version_ |
1718402411565940736 |